Market Overview
Global Biomarker Testing market reached US$ YY million in 2023 and is expected to reach US$ YY million by 2031, growing at a CAGR of YY% during the forecast period 2024-2031.
Biomarker testing is the use of a laboratory test to measure biomarkers found in blood, other body fluids, or tissue. Biomarker testing can be somatic or germline. Biomarker testing is also done to select treatments for people who are diagnosed with certain types of cancer.
Biomarker testing helps patient receive the specific treatment best suited to combat their specific disease. A growing majority of new trial results and FDA approvals in cancer, for instance, are for targeted therapies with associated biomarkers.
Market Scope
| Metrics | Details |
| CAGR | YY% |
| Market Size Available for Years | 2022-2031 |
| Estimation Forecast Period | 2024-2031 |
| Revenue Units | Value (US$ Mn) |
| Segments Covered | Test Type, Biomarker Type, Application, End-User |
| Regions Covered | North America, Europe, Asia-Pacific, South America, and Middle East & Africa |
| Largest Region | North America |
| Fastest Growing Region | Asia-Pacific |
| Report Insights Covered | Competitive Landscape Analysis, Company Profile Analysis, Market Size, Share, Growth, Demand, Recent Developments, Mergers and Acquisitions, New Product Launches, Growth Strategies, Revenue Analysis, Porter’s Analysis, Pricing Analysis, Regulatory Analysis, Supply-Chain Analysis and Other key Insights. |
For more details on this report – Request for Sample
Market Dynamics: Drivers & Restraints
Rising research and development of new biomarker tests
The increasing research and development of biomarker testing methods is expected to drive market growth. The development of new biomarker tests helps in identifying a wider range of diseases and conditions earlier and more accurately. This allows for better disease management, improved patient outcomes, and potentially earlier interventions to prevent disease progression.
Major players are introducing novel testing methods for the identification and treatment of various diseases which is expected to drive the market growth. For instance, in March 2024, LabCorp launched its biomarker test to identify the presence or absence of phosphorylated tau 217 (pTau217), a pivotal blood biomarker designed to aid in the diagnosis of Alzheimer's disease and the subsequent monitoring of patients undergoing treatment with new Alzheimer's disease therapies.
Additionally, in October 2023, Lucent Diagnostics expanded its LucentAD product line with the addition of a high-accuracy p-Tau 217 blood test for Alzheimer’s disease – LucentAD p-Tau 217. This test marks a major advance in the performance of scalable immunoassay-based blood biomarker tests intended for assessing amyloid pathology in individuals with memory complaints. Thus, the above factors are expected to drive the market growth.
High costs of test development
The market is expected to be hampered by the development costs of the tests. Developing and validating new biomarker tests is expensive which requires a significant investment in research and clinical trials. This can limit the number of new biomarkers available for testing.
Segment Analysis
The global biomarker testing market is segmented based on test type, biomarker type, application, end-user and region.
Tumor Testing segment is expected to dominate the market growth
It is anticipated that the biomarker testing industry will be dominated by the tumor testing segment. The prevalence of cancer is rising making it one of the world's leading causes of death. The need for diagnostic instruments to identify, categorize, and track cancer is fueled by the rising number of cancer cases. Tumour testing is becoming more common as people are becoming more aware of cancer diagnosis and treatment.
For instance, according to the report published by the National Library of Medicine in 2024, 2,001,140 new cancer cases and 611,720 cancer deaths are projected to occur in the United States.
Additionally, the World Health Organization in 2022, has estimated that around 53.5 million individuals have been diagnosed with cancer and are living for more than 5 years. Thus, the above factors are expected to hold the segment in the dominant position in the market share.
Geographical Analysis
North America is expected to hold a significant position in biomarker testing market share
North America boasts a well-established network of research institutions, universities, and pharmaceutical companies heavily invested in biomarker discovery and development. This strong foundation in R&D fuels innovation and leads to the creation of new biomarker tests at a rapid pace. The increasing launches of tests, strategies by the major players in the region and the increasing funds for the research activities by the government are expected to hold the region in the dominant position.
For instance, in August 2023, Quest Diagnostics entered into a partnership with Envision Sciences for the commercial launch of a novel prostate cancer biomarker test for identification of severe and aggressive forms of the disease.
Additionally, in July 2023, Quanterix Corporation launched LucentAD, a test to assist in the evaluation of patients experiencing cognitive symptoms consistent with the early signs of Alzheimer’s disease (AD). Thus, the above factors are expected to drive the market growth in the region and are expected to hold the dominant position in the market share.
COVID-19 Impact Analysis
COVID-19 has a positive impact on the market growth. The market was stimulated by the increased need for blood gas monitoring equipment in clinics and hospitals. Point-of-care blood gas monitors have grown in value because of their portability and speedy results delivery, which help COVID-19 patients make timely treatment decisions. However, lockdowns and travel restrictions caused delays in the production and delivery of medical supplies, notably blood gas monitors, which resulted in a shortage of equipment in some areas. Thus, the pandemic has a moderate impact on the market.
Competitive Landscape
The major global players in the market include QIAGEN N.V., Bio-Rad Laboratories, Inc., Illumina, Inc., Labcorp Drug Development, IQVIA, Inc., Quanterix Corporation, Merck KGaA, Abbott Laboratories, Thermo Fisher Scientific Inc., and Q2 Solutions among others.
Why Purchase the Report?
- To visualize the global biomarker testing market segmentation based on test type, biomarker type, application, end-user and region as well as understand key commercial assets and players.
- Identify commercial opportunities by analyzing trends and co-development.
- Excel data sheet with numerous data points of biomarker testing market-level with all segments.
- PDF report consists of a comprehensive analysis after exhaustive qualitative interviews and an in-depth study.
- Product mapping available as excel consisting of key products of all the major players.
The global biomarker testing market report would provide approximately 53 tables, 47 figures and 176 pages.
Target Audience 2025
- Manufacturers/ Buyers
- Industry Investors/Investment Bankers
- Research Professionals
- Emerging Companies
